Ningxia Wu

Dr. Ningxia Wu


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
NWNingxia Wu
Ningxia Wu
FMFengbo Miao
Fengbo Miao
YWYu Jia Wang
Yu Jia Wang
YLYinglei Li
Yinglei Li
SSShuang Song
Shuang Song
FCFeng Cao
Feng Cao
(1) Background: Cardiac magnetic resonance (CMR) is a non-invasive modality for myocardial tissue characterization in coronary artery disease (CAD), but optimizing its efficiency for clinical decision-making in high-risk patients with suspected obstructive coronary artery disease still remains challenging. (2) Objectives: This study aimed to develop and internally validate an interpretable multimodal prediction integrating CMR imaging, clinical variables, and laboratory biomarkers for risk stratification in high-risk patients with persistent suspicion of obstructive CAD after CMR. (3) Methods: Among 1296 patients with suspected CAD who underwent CMR, 325 were confirmed to have CAD. Of these, 239 underwent invasive CAG (derivation cohort) and 86 underwent coronary computed tomography angiography (CTA, Cross-Modality Applicability-Boundary Testing cohort, deliberately designed to define the model’s applicable scope rather than conventional multicenter external validation). Three hierarchical models were developed: laboratory-only (Model 1), imaging-only (Model 2), and multimodal integration (Model 3). Performance was evaluated using area under the curve (AUC), calibration curves, decision curve analysis, and SHapley Additive exPlanations (SHAP). A point-score SHAP-visualization plot was generated to illustrate relative feature contributions of the multimodal model. (4) Results: The optimal multimodal achieved an AUC of 0.920 (95% CI 0.873–0.960), significantly outperforming laboratory-only (AUC 0.719, p < 0.001) and imaging-only models (AUC 0.888, p < 0.001). Cross-modality applicability-boundary testing in the CTA cohort (n = 86) demonstrated expected performance attenuation (AUC = 0.611), indicating that this model is intended for high-risk patients referred for invasive angiography rather than unselected CTA screening. SHAP analysis identified cardiomyopathy type, E-wave velocity, and aortic annulus diameter as top predictors. (5) Conclusions: This interpretable multimodal prediction reliably showed promising internal discrimination for obstructive CAD risk stratification but demonstrated imperfect calibration and limited cross-modality performance. Prospective multicenter external validation is mandatory before any clinical-decision-support deployment.